Teva Pharmaceuticals has reportedly lost a battle to have a generic form of its multiple sclerosis drug be blocked from entering the market 10 days before Teva’s patent expires.
According to reports, the Israel-based pharmaceutical company filed a lawsuit against the US Food and Drug Administration accusing the regulator of failing …read more
Source: Global Competition Law Blogs